10-Q 1 ten-q.txt 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2002 ( ) TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File No. 1-12031 UNIVERSAL DISPLAY CORPORATION ------------------------------------------------------ (Exact Name of Registrant as Specified in Its Charter) PENNSYLVANIA 23-2372688 ------------------------------------ --------------------- (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 375 Phillips Boulevard Ewing, New Jersey 08618 ---------------------------------------------------- ------------- (Address of Principal Executive Offices) (Zip Code) (609) 671-0980 -------------------------------------------------- (Registrant's Telephone Number, Including Area Code) Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] APPLICABLE ONLY TO CORPORATE ISSUERS Indicate the number of shares outstanding of each of the issuer's classes of Common Stock, as of the latest practicable date: As of August 12, 2002, the registrant had outstanding 19,750,416 shares of Common Stock, par value $.01 per share. INDEX PAGE Part I - Financial Information Item 1. Unaudited Financial Statements Consolidated Balance Sheets June 30, 2002 and December 31, 2001 3 Consolidated Statements of Operations - Three months ended June 30, 2002 and 2001, and inception to June 30, 2002 4 Consolidated Statements of Operations - Six months ended June 30, 2002 and 2001, and inception to June 30, 2002 5 Consolidated Statements of Cash Flows - Six months ended June 30, 2002 and 2001, and inception to June 30, 2002 6 Notes to Consolidated Financial Statements 7-14 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 14-17 Item 3. Quantitative and Qualitative Disclosures About Market Risk 17 Part II - Other Information Item 4. Submission of Matters to Vote of Security Holders 18 Item 6. Exhibits and Reports on Form 8-K 18
2 PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARY (a development-stage company) CONSOLIDATED BALANCE SHEETS (unaudited)
June 30, 2002 December 31, 2001 ------------- ---------------- ASSETS CURRENT ASSETS: Cash and cash equivalents (See Note 2) $ 4,403,484 $ 7,883,132 Short-term investments (See Note 2) 2,978,555 4,516,199 Restricted cash (See Note 6) 15,119,781 15,162,414 Accounts receivables 450,592 540,855 Prepaid and other current assets 416,669 355,820 ------------- ------------- Total current assets 23,369,081 28,458,420 PROPERTY AND EQUIPMENT, net 5,447,231 5,296,177 ACQUIRED TECHNOLOGY, net 13,947,311 14,794,847 OTHER ASSETS 39,976 20,125 ------------- ------------- Total assets $ 42,803,599 $ 48,569,569 ============= ============= LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Convertible promissory notes (face value of $15,000,000, net of discounts) $ 10,384,681 $ 8,288,239 Capital lease obligations 4,464 4,228 Accounts payable 320,506 649,100 Accrued expenses 793,182 1,072,621 Deferred revenues 1,066,667 450,000 ------------- ------------- Total current liabilities 12,569,500 10,464,188 ------------- ------------- CAPITAL LEASE OBLIGATIONS 6,306 8,599 ------------- ------------- SHAREHOLDERS' EQUITY Preferred Stock, par value $0.01 per share, 5,000,000 shares authorized, 200,000 shares Series A Nonconvertible Preferred Stock, par value $.01 per share, issued and outstanding (liquidation value of $7.50 per share, $1,500,000 in the aggregate) and 300,000 shares Series B Convertible Preferred Stock issued and outstanding (liquidation value of $21.48 per share, $6,444,000 in the aggregate) 5,000 5,000 Common Stock, par value $.01 per share, 50,000,000 shares authorized, 18,273,593 and 18,093,124 issued and outstanding, respectively 182,736 180,931 Additional paid-in capital 88,019,969 85,016,601 Accumulated other comprehensive loss (1,491) (3,925) Deficit accumulated during development-stage (57,978,421) (47,101,825) ------------- ------------- Total shareholders' equity 30,227,793 38,096,782 ------------- ------------- Total liabilities and shareholders' equity $ 42,803,599 $ 48,569,569 ============= =============
The accompanying notes are an integral part of these statements. 3 UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARY (a development-stage company) CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
Three Months Ended June 30, Period from Inception ------------------------------- (June 17, 1994) to 2002 2001 June 30, 2002 ------------ ------------ -------------------- REVENUE: Contract research revenue $ 364,976 $ 254,671 $ 3,345,321 Development chemicals 90,050 2,488 372,223 ------------ ------------ ------------- Total revenue 455,026 257,159 3,717,544 ------------ ------------ ------------- OPERATING EXPENSES: Research and development 3,762,970 4,063,480 38,932,134 General and administrative 1,320,303 1,067,141 18,047,750 ------------ ------------ ------------- Total operating expenses 5,083,273 5,130,621 56,979,884 ------------ ------------ ------------- Operating loss (4,628,247) (4,873,462) (53,262,340) INTEREST INCOME 118,936 104,880 1,872,907 INTEREST EXPENSE (1,068,476) -- (4,071,652) ------------ ------------ ------------- NET LOSS (5,577,787) (4,768,582) (55,461,085) DEEMED DIVIDEND TO PREFERRED SHAREHOLDERS -- -- (2,517,336) ------------ ------------ ------------- NET LOSS APPLICABLE TO COMMON SHAREHOLDERS $ (5,577,787) $ (4,768,582) $ (57,978,421) ============ ============ ============= BASIC AND DILUTED NET LOSS PER COMMON SHARE $ (0.31) $ (0.28) ============ ============ WEIGHTED AVERAGE SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE 18,183,254 16,903,060 ============ ============
The accompanying notes are an integral part of these statements. 4 UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARY (a development-stage company) CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
Six Months Ended June 30, Period from Inception ------------------------------- (June 17, 1994) to 2002 2001 June 30, 2002 ------------ ------------ --------------------- REVENUE: Contract research revenue $ 812,059 $ 454,913 $ 3,345,321 Development chemicals 177,893 8,298 372,223 ------------ ------------ ------------ Total revenue 989,952 463,211 3,717,544 ------------ ------------ ------------ OPERATING EXPENSES: Research and development 7,616,797 7,325,709 38,932,134 General and administrative 2,273,539 1,925,623 18,047,750 ------------ ------------ ------------ Total operating expenses 9,890,336 9,251,332 56,979,884 ------------ ------------ ------------ Operating loss (8,900,384) (8,788,121) (53,262,340) INTEREST INCOME 247,298 240,560 1,872,907 INTEREST EXPENSE (2,223,510) -- (4,071,652) ------------ ------------ ------------ NET LOSS (10,876,596) (8,547,561) (55,461,085) DEEMED DIVIDEND TO PREFERRED SHAREHOLDERS -- -- (2,517,336) ------------ ------------ ------------ NET LOSS APPLICABLE TO COMMON SHAREHOLDERS $(10,876,596) $ (8,547,561) $(57,978,421) ============ ============ ============ BASIC AND DILUTED NET LOSS PER COMMON SHARE $ (0.60) $ (0.51) ============ ============ WEIGHTED AVERAGE SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE 18,181,230 16,809,118 ============ ============
The accompanying notes are an integral part of these statements. 5 UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARY (a development-stage company) CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
Six Months Ended June 30, Period from Inception ------------------------------ (June 17, 1994) to 2002 2001 June 30, 2002 ----------- ---------- --------------------- CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ (10,876,596) $ (8,547,561) $ (55,461,085) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 823,605 520,592 2,662,133 Amortization of intangibles 847,536 847,536 3,003,407 Amortization of discounts on Convertible Promissory Note 2,096,442 -- 3,786,143 Issuance of Common Stock options and warrants for services 91,022 58,080 1,159,014 Issuance of Common Stock and warrants in connection with amended research and license agreements -- -- 3,120,329 Issuance of Common Stock in connection with executive compensation 16,150 -- 439,370 Issuance of redeemable Common Stock, Common Stock options and warrants in connection with development agreement 2,852,777 1,453,810 5,799,070 Issuance of Common Stock options and warrants for Scientific Advisory Board -- 1,712,736 1,947,369 Acquired in-process technology -- -- 350,000 (Increase) decrease in assets: Accounts Receivables 90,263 (9,609) (450,592) Other current assets (60,849) (230,812) 12,316 Other assets (19,851) 17,347 (39,976) Increase (decrease) in liabilities: Accounts payable and accrued expenses (580,560) (846,184) 814,437 Payable to related parties -- -- 250,000 Deferred revenue 616,667 200,000 1,066,667 ------------ ------------ ------------ Net cash used in operating activities (4,103,394) (4,824,065) (31,541,398) ------------ ------------ ------------ CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of equipment (974,659) (605,593) (7,227,343) Purchase of intangibles -- -- (25,750) Purchases of short-term investments (2,511,506) (4,170,361) (28,477,413) Proceeds from sale of short-term investments 4,051,585 2,676,000 25,497,368 Restricted cash 42,633 -- (15,119,781) ------------ ------------ ------------ Net cash provided by (used in) investing activities 608,053 (2,099,954) (25,352,919) ------------ ------------ ------------ CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of Common Stock -- 1,348,984 22,976,751 Proceeds from issuance of Preferred Stock -- -- 9,137,079 Proceeds from issuance of Convertible Promissory Note -- -- 15,000,000 Proceeds from the exercise of Common Stock options and warrants 17,750 1,041,310 14,193,222 Principal payments on capital lease (2,057) (1,845) (9,251) ------------ ------------ ------------ Net cash provided by financing activities 15,693 2,388,449 61,297,801 ------------ ------------ ------------ INCREASE(DECREASE) IN CASH AND CASH EQUIVALENTS (3,479,648) (4,535,570) 4,403,484 CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 7,883,132 7,701,040 -- ------------ ------------ ------------ CASH AND CASH EQUIVALENTS, END OF PERIOD $ 4,403,484 $ 3,165,470 $ 4,403,484 ============ ============ ============
The accompanying notes are an integral part of these statements. 6 UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARY (a development-stage company) NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) NOTE 1. BACKGROUND Universal Display Corporation (the "Company"), a development-stage company, is engaged in the research and development and commercialization of organic light emitting diode ("OLED") technology for potential flat panel display applications. The Company, formerly known as Enzymatics, Inc. ("Enzymatics"), was incorporated under the laws of the Commonwealth of Pennsylvania on April 24, 1985 and commenced its current business activities on August 1, 1994. The New Jersey corporation formerly known as Universal Display Corporation ("UDC") was incorporated under the laws of the State of New Jersey on June 17, 1994. UDC was renamed UDC, Inc. on December 14, 1995 and is a wholly-owned subsidiary of the Company. Research and development of the OLED technology is being conducted at the Advanced Technology Center for Photonics and Optoelectronic Materials at Princeton University and at the University of Southern California ("USC") (on a subcontract basis with Princeton University), pursuant to a Sponsored Research Agreement dated August 1, 1994, as amended (the "1994 Sponsored Research Agreement"), originally between the Trustees of Princeton University ("Princeton University") and American Biomimetics Corporation ("ABC"), a privately held Pennsylvania corporation and affiliate of the Company. In October 1997, the Company entered into a new 5-year Sponsored Research Agreement with Princeton University and USC (the "1997 Sponsored Research Agreement") for research and development of the OLED technology (Note 3). In the second quarter, the Company amended the 1997 Sponsored Research Agreement with Princeton providing, iner-alia, for an additional five-year term, extending it through July 31, 2007. Pursuant to a license agreement dated August 1, 1994 (the "1994 License Agreement") between Princeton University and ABC, assigned to the Company by ABC in June 1995, the Company has a worldwide exclusive license to manufacture and market products based on Princeton University's pending patent application relating to the OLED technology and the right to obtain a similar license to inventions conceived or discovered under the 1994 Sponsored Research Agreement and to sublicense such rights. In October 1997, the Company amended the 1994 License Agreement (the "1997 Amended License Agreement") to modify certain terms of the license (Note 3). The Company is also engaged in research, development and commercialization activities at its 21,000 square foot facility leased in Ewing, New Jersey. In 1999 the Company entered into a lease for 11,000 square feet. The Company moved its operations to this facility in the fourth quarter of 1999. In the second quarter of 2001, the Company signed a lease for an additional 10,000 square feet. The Company is a development-stage entity with no significant operating activity to date. Expenses incurred have primarily been in connection with research and development funding and activities, obtaining financing and administrative activities. The developmental nature of the activities is such that significant inherent risks exist in the Company's operations. Completion of the commercialization of the Company's technology will require funds substantially greater than the Company currently has available. There is no assurance that such financing will be available to the Company, on commercially reasonable terms or at all. The Company anticipates, based on management's internal forecasts and assumptions relating to its operations, that it has sufficient cash, cash equivalents and short term investments to meet its obligations through at least the end of its current fiscal year, which will end December 31, 2002. To the extent that Princeton University's research efforts do not result in the development of commercially viable applications for the OLED technology, the Company will not have any meaningful operations. Even if a product incorporating the OLED technology is developed and introduced into the marketplace, additional time and funding may be necessary before significant revenues are realized. While the Company funds the OLED technology research, the scope of and technical aspects of the research and the resources and efforts directed to such research are subject to the control of Princeton University and the principal investigators. 7 Accordingly, the Company's success is dependent on the efforts of Princeton University and the principal investigators. The 1997 Sponsored Research Agreement provides that if certain of the principal investigators are unavailable to continue to serve as principal investigators, because such persons are no longer associated with Princeton University or otherwise, and successors acceptable to both the Company and Princeton University are not available, the 1997 Sponsored Research Agreement will terminate. NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES INTERIM FINANCIAL INFORMATION In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position as of June 30, 2002, the results of operations for the three and six months ended June 30, 2002 and 2001, and cash flows for the six months ended June 30, 2002 and 2001. Interim results may not be indicative of the results that may be expected for the year. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company's latest year-end financial statements, which were included in the Company's Annual Report on Form 10-K for the year ended December 31, 2001. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of Universal Display Corporation and its wholly owned subsidiary, UDC, Inc. All significant intercompany transactions and accounts have been eliminated. USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company classifies its existing marketable securities as available-for-sale in accordance with the provisions of Statement of Financial Accounting Standards No. 115, "Accounting for Certain Investments in Debt and Equity Securities." These securities are carried at fair market value, with unrealized gains and losses reported in shareholders' equity as a component of other comprehensive income (loss). Gains or losses on securities sold are based on the specific identification method. The Company reported unrealized holding losses of $1,491 and $3,925 at June 30, 2002 and December 31, 2001, respectively. At June 30,2001 there were no unrealized gains or losses reported. Comprehensive loss, which includes the net loss and change in unrealized holding losses, was $10,874,162 and $8,547,561 for the six months ended June 30, 2002 and 2001, respectively and $5,574,113 and $4,768,582 for the three months ended June 30, 2002 and 2001, respectively. FAIR VALUE OF FINANCIAL INSTRUMENTS Cash and cash equivalents, short-term investments, restricted cash, accounts receivables, prepaid and other current assets, accounts payable and accrued expenses are reflected in the accompanying financial statements at fair value due to the short-term nature of those instruments. The carrying amount of capital lease obligations approximate fair value at the balance sheet dates. The carrying amount of the convertible promissory notes approximates fair value at June 30, 2002 (Note 6). 8 PROPERTY AND EQUIPMENT Property and equipment are stated at cost and depreciated on a straight-line basis over 3 to 7 years for office and lab equipment, furniture and fixtures, and the lesser of the lease term or useful life for leasehold improvements. Repair and maintenance costs are charged to expense as incurred. Additions and betterments are capitalized. ACQUIRED TECHNOLOGY Acquired technology consists of acquired license rights for patents and know-how obtained from PD-LD, Inc. and Motorola (Note 4). The intangible asset consists of the following:
June 30, 2002 December 31, 2001 ------------- ----------------- PD-LD, Inc. $ 1,481,250 $ 1,481,250 Motorola 15,469,468 15,469,468 ------------- ------------- 16,950,718 16,950,718 Less: Accumulated amortization (3,003,407) (2,155,871) ------------- ------------- Acquired Technology, net $ 13,947,311 $ 14,794,847 ============= =============
Acquired technology is amortized on a straight-line basis over its estimated useful life of ten years. LONG-LIVED ASSETS Management continually evaluates whether events and circumstances have occurred that indicate that the remaining estimated useful life of long-lived assets may warrant revision or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of the impairment will be based on generally accepted valuation methodologies, as deemed appropriate. As of June 30, 2002 and December 31, 2001, management believes that no revision to the remaining useful lives or write-down of long-lived assets is required. NET LOSS PER COMMON SHARE Basic earnings per share (EPS) is computed by dividing net loss applicable to Common shareholders by the weighted-average number of Common shares outstanding for the period. Diluted EPS reflects the potential dilution from the exercise or conversion of securities into Common Stock. For the three and six months ended June 30, 2002 and 2001 the effects of the exercise of 7,303,703 and 5,863,741 outstanding stock options and warrants, respectively, were excluded from the calculation of diluted EPS as the impact would be antidilutive. REVENUE RECOGNITION AND DEFERRED REVENUE Contract revenues represent reimbursements by government entities for all or a portion of the research and development costs the Company incurs related to the contracts. Revenues are recognized proportionally as the research and development costs are incurred. Development chemical revenues represent the sale of evaluation chemicals to potential OLED display manufacturers. The chemicals are used to evaluate the Company's proprietary OLED material system. 9 Revenues are recognized at the time of shipment and passage of title. The Company also receives non-refundable advanced license payments in connection with certain joint development and technology evaluation agreements it enters into. These payments are deferred until a license agreement is executed or negotiations have ceased and there is no likelihood of executing a license agreement. Revenues will be recorded over the expected life of the licensed technology, if there is an effective license agreement, or at the time the negotiations show no likelihood of an executable license agreement. RESEARCH AND DEVELOPMENT Expenditures for research and development are charged to operations as incurred. RECENT ACCOUNTING PRONOUNCEMENTS In July 2001, the Financial Accounting Standards Board ("FASB") issued Statements of Financial Accounting Standards ("SFAS") No. 141, Business Combinations (SFAS No. 141), and SFAS No. 142, "Goodwill and Other Intangible Assets" (SFAS No. 142), which are effective for fiscal years beginning after December 15, 2001. SFAS No. 141 requires all business combinations initiated after June 30, 2001, to be accounted for using the purchase method. SFAS No. 142 no longer requires the amortization of goodwill; rather, goodwill will be subject to at least an annual assessment for impairment by applying a fair-value-based test. In addition, an acquired intangible asset should be separately recognized if the benefit of the intangible asset is obtained through contractual or other legal rights, or if the intangible asset can be sold, transferred, licensed, rented, or exchanged, regardless of the acquirer's intent to do so. Such acquired intangible asset will be amortized over the estimated useful lives. The adoption of SFAS 142 had no effect on the consolidated financial statements. In August 2001, the FASB issued SFAS No. 143, "Accounting for Asset Retirement Obligations" ("SFAS No. 143"), which is effective for fiscal years beginning after June 15, 2002. SFAS No. 143 addresses accounting and reporting for obligations associated with the retirement of tangible long-lived assets and retirement of assets. The Company does not expect the adoption of SFAS No. 143 to have an impact on the consolidated financial statements. In October 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS No. 144"). SFAS No. 144 changes the accounting for long-lived assets by requiring that all long-lived assets be measured at the lower of carrying amount or fair value less cost to sell, whether included in reporting continuing operations or in discontinued operations. SFAS No. 144, which replaces SFAS 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of" is effective for fiscal years beginning after December 15, 2001. The adoption of SFAS No. 144 had no impact on the consolidated financial statements. In April 2002, the FASB issued SFAS No. 145, Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections. The Statement updates, clarifies and simplifies existing accounting pronouncements relating to gains and losses from extinguishment of debt and certain lease modifications. Certain provisions of SFAS No. 145 are effective for fiscal years beginning after May 15, 2002, while other provisions are effective for transactions occurring after May 15, 2002. The adoption of SFAS No. 145 is not expected to have a material impact on the Company's results of operations or financial position. In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities, which requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred and nullifies EITF 94-3. The Company plans to adopt SFAS No. 146 in January 2003. Management believes that the adoption of this statement will not have a material effect on the Company's future results of operation or financial position. STATEMENT OF CASH FLOW INFORMATION The following non-cash investing and financing activities occurred:
Six months ended June 30, --------------------------- 2002 2001 ---- ---- Common Stock, options and warrants to acquire Common Stock in development agreement (Note 5) $ 2,852,777 $ 1,453,810 Common Stock issued for the purchase of equipment -- 43,776 ----------- ----------- $ 2,852,777 $ 1,453,810 =========== ===========
10 STOCK OPTIONS The Company accounts for its stock option plans under Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," under which no compensation cost has been recognized for options issued to employees at fair market value on the date of grant. In 1995, the Financial Accounting Standards Board issued SFAS No. 123, "Accounting for Stock-Based Compensation." SFAS No. 123 established a fair value based method of accounting for stock-based compensation plans. SFAS No. 123 requires that a company's financial statements include certain disclosures about stock-based employee compensation arrangements regardless of the method used to account for the plan. The Company accounts for its stock option and warrant grants to non-employees in exchange for goods or services in accordance with SFAS No. 123 and Emerging Issues Task Force No. 96-18 ("EITF 96-18"). SFAS 123 and EITF 96-18 require that the Company account for its option and warrant grants to non-employees based on the fair value of the options and warrants granted. NOTE 3. SPONSORED RESEARCH AGREEMENT WITH PRINCETON UNIVERSITY On October 9, 1997, the Company entered into the 1997 Sponsored Research Agreement with Princeton University and entered into a 1997 Amended License Agreement with Princeton University and USC amending its 1994 License Agreement with Princeton University. The 1997 Sponsored Research Agreement continues and expands the sponsored research, which commenced in 1994 under which the Company funds additional research and development work at Princeton University (and at USC under a subcontract with Princeton University) in OLED technology. The 1997 Sponsored Research Agreement requires the Company to pay up to $4.4 million commencing on July 31, 1998 through July 31, 2002. In April 2002, the Company amended the 1997 Sponsored Research Agreement with Princeton providing, iner-alia, for an additional five-year term. The Company is obligated to pay Princeton up to $7.5 million commencing on July 31, 2002 through July 31, 2007. The amounts due to Princeton University are charged to expense when paid by the Company. Under the 1997 License Agreement, the Company has the worldwide exclusive and perpetual license to manufacture and market products, and to sublicense those rights, based on Princeton University's and USC's pending patent applications relating to the OLED technology and conceived under the 1994 and 1997 Sponsored Research Agreements. The Company is required to pay Princeton University a royalty of 3% of the Company's net sales of products utilizing the OLED technology. In circumstances where the Company sublicenses the OLED technology (except to affiliates), the royalty required to be paid by the Company was reduced in the 1997 License Agreement from 50% to 3%. These royalty rates are subject to upward adjustments under certain conditions. Under the 1997 Amended License Agreement, the Company is obligated to pay to Princeton University minimum royalties of $100,000 per year. Accordingly, the Company accrued $50,000 of research and development expense for the six months ended June 30, 2002 for the minimum royalties due. In order to protect Princeton University's tax exempt status, the 1997 License Agreement provides that Princeton University may, in its sole discretion, determine whether, pursuant to the provisions of the Tax Reform Act of 1986, it is required to negotiate the royalties and other considerations payable to Princeton University on products not reasonably conceivable by the parties at the time of execution of the 1994 License Agreement. If Princeton University reasonably concludes that the consideration payable by the Company for any such product is not fair and competitive, Princeton University may exercise its right to renegotiate the royalties and other consideration payable by the Company for any such product prior to the expiration of 180 days after the first patent is filed or other intellectual property protection is sought. The Company has the right to commence arbitration proceedings to challenge Princeton University's exercise of such renegotiation rights. If the parties are unable to agree to royalties and other consideration for such products within a specified period of time, then Princeton University is free to license to third parties without repayment of any funds provided under the 1997 Sponsored Research Agreement. NOTE 4. ACQUIRED TECHNOLOGY On July 19, 2000, the Company, PD-LD, Inc. ("PD-LD") and Princeton University entered into a Termination, Amendment and License Agreement whereby the Company acquired all PD-LD's rights to certain issued and pending patents and technology known as organic vapor phase deposition ("OVPD") in 11 exchange for 50,000 shares of the Company's Common Stock. Pursuant to this transaction, the Company has included in its License Agreement with Princeton the exclusive license to all Princeton patents and technology related to OVPD, whether developed pursuant to its research agreements with Princeton or otherwise. The acquisition of these patents had a fair value of $1,481,250 (Note 2). On September 29, 2000, the Company entered into a license agreement with Motorola, Inc. ("Motorola"). Pursuant to the license agreement, the Company licensed from Motorola 72 US patents, 6 US patent applications, and additional foreign patents. These patents expire between 2012 and 2018. The Company has the sole right to sublicense these Motorola patents to manufacturers. As consideration for the licenses, the Company issued to Motorola 200,000 shares of Common Stock (valued at $4,412,500), 300,000 shares of Series B Convertible Preferred Stock (valued at $6,618,750), and a warrant to purchase 150,000 shares of Common Stock at $21.60 per share. The warrant became exercisable on September 29, 2001 and will remain exercisable until September 29, 2008. The warrant was recorded at fair market value of $2,206,234 based on the Black-Scholes option-pricing model and was recorded as a component of the costs of the acquired technology. The Company also issued a warrant to acquire 150,000 shares of Common Stock as a finder's fee in connection with this transaction. The warrant was granted with an exercise price of $21.60 per share. The warrant was exercisable upon its granting immediately and will remain exercisable until September 29, 2007. This warrant was accounted for at its fair value based on the Black-Scholes option pricing model and $2,206,234 was recorded as a component of the cost of the acquired technology. The Company used the following assumptions in the Black-Scholes option pricing model for the 300,000 warrants issued in connection with this transaction: (1) 6.3% risk-free interest rate, (2) expected life of 7 years, (3) 60% volatility, and (4) zero expected dividend yield. In addition, the Company incurred $25,750 of direct cash transaction costs that have been included in the cost of the acquired technology. In total, the Company recorded an intangible asset of $15,469,468 for the technology acquired from Motorola (Note 2). In addition, the Company will pay to Motorola a royalty based on future sales of products incorporating OLED technology. Such royalty payments may be made, at the Company's discretion, in either all cash or (50%) cash and (50%) in shares of Common Stock. The number of shares of Common Stock used to pay the royalty portion shall be equal to 50% of the royalty due divided by the average daily closing price per share of stock over the ten trading days ending two business days prior to the date the Common Stock is issued. NOTE 5. COMMON STOCK AND WARRANTS ISSUED IN DEVELOPMENT AND LICENSE AGREEMENT On October 1, 2000, the Company entered into a 5 year Development and License Agreement with PPG Industries, Inc. ("PPG") to leverage the Company's OLED flat panel display technology with PPG's expertise in the development and manufacturing of organic materials. A team of PPG scientists and engineers are assisting the Company in developing and commercializing its proprietary OLED material system. In consideration for PPG's services under the agreement, the Company will issue shares of Common Stock and warrants to acquire Common Stock to PPG on an annual basis over the period from January 1, 2001 through December 31, 2005. The amount of securities issued is subject to adjustment under certain circumstances, as defined in the agreement. In accordance with the PPG agreement, the Company issued 3,019 shares of Common Stock in February 2002. The additional shares were issued as a result of the final accounting for actual costs incurred by PPG in 2001. Accordingly, the Company accrued $27,473 of research and development expense as of December 31, 2001 based on the fair value of the additional shares. In accordance with the agreement, the Company also issued warrants to PPG to acquire 121,843 shares of Common Stock as part of the consideration for services performed during 2001. The warrants were earned during 2001, but were not issued until February 2002. The number of warrants earned and issued is based on the number of shares of Common Stock earned by, and issued, to PPG by the Company during the calendar year. During the first quarter of 2002 and 2001, the Company issued 344,379 and 118,824 shares of Common Stock, respectively, to PPG as consideration for services required under the agreement for 2002 and 2001. 12 Under Emerging Issues Task Force Topic D-90, equity instruments that are conditionally transferred to another party and subject to forfeiture for non-performance of future goods or services, should not be considered issued for accounting purposes until such time as performance has occurred. Accordingly, the Company will record the issuance of the shares as they are earned. For the six months ended June 30, 2002 and 2001, PPG earned 170,950 and 59,796 shares of the Company's Common Stock, respectively. The Company recorded a charge to research and development expense of $1,529,977 and $811,623 during the six months ended June 30, 2002 and 2001, respectively, representing the fair value of the shares earned. During the six months ended June 30, 2002 and 2001, the Company also recorded a charge to research and development expense of $1,238,847 and $661,984, respectively. This charge was recorded based on the estimated fair value of warrants that were earned by PPG during these periods. The Company determined the fair value of the warrants earned during 2002 and 2001 using the Black-Scholes option-pricing model with the following assumptions: (1) risk free interest rate of 4.52% and 5.595%, (2) no expected dividend yield, (3) expected life of 7 years, and (4) expected volatility of 94% and 70%, respectively. In accordance with the terms of the PPG agreement, on December 14, 2000, UDC granted options to PPG employees to acquire 26,000 shares of Common Stock. These options vested over a one-year period, have an exercise price of $9.44 per share and expire in 10 years. During the six months ended June 30, 2001, the Company recorded a charge of $144,703, to research and development expense for the fair market value, determined in accordance with the Black-Scholes option-pricing model, of the stock option awards that were earned. On December 17, 2001, the Company granted an additional 26,333 options to PPG employees. These options vest over a one-year period , have an exercise price of $8.56 per share and expire in 10 years. During the six months ended June 30, 2002, the Company recorded $83,954 in research and development costs related to these options. The Company determined the fair value of the options earned during the six months ended June 30, 2002 and 2001 using the Black-Scholes option-pricing model with the following assumptions: (1) risk free interest rate of 5.421% and 5.595%, (2) no expected dividend yield, (3) expected life of 10, and (4) expected volatility of 94% and 70%, respectively. NOTE 6. RESTRICTED CASH AND CONVERTIBLE PROMISSORY NOTES In August 2001, the Company issued two $7,500,000 Notes with a maturity date of August 22, 2004, in connection with a private placement. Interest accrues daily on the outstanding principal amount of the Notes but compounds annually at a rate per year equal to the rate of interest paid from time to time on money market accounts held at First Union National Bank, and is payable quarterly in cash. Upon the occurrence and during the continuance of an event of default under the Notes, the interest rate increases to 18% per year. As of June 30, 2002, the Company was not in default. The Notes are convertible into shares of the Company's Common Stock at a price per share equal to the conversion price then in effect. The initial conversion price of the Notes is $13.97, and may change in the future based on certain anti-dilution and other adjustments. In August 2002, the Company completed a registered direct offering to institutional investors, which was deemed dilutive under the terms of the Notes. As a result, the conversion price of the Notes was reduced to $5.09. The Notes automatically convert into Common Stock if certain conditions, which are outside the control of the holders and the Company, are met. The Notes are convertible at the election of the holders or the Company if certain conditions, which are outside the control of the holders and the Company, are met. The Company's obligations under the Notes are secured by irrevocable letters of credit issued with a face amount equal to the outstanding principal of the related Notes. The $15,000,000 in proceeds from the sale of the Notes has been pledged as collateral to the bank issuing the letters of credit. Under the terms of the applicable agreements, the face amount of each letter of credit is reduced as the outstanding principal amount of the related Note is reduced. Thus, as each Note is converted, the face amount of the related letter of credit will be reduced and, likewise, the amount pledged to the bank as collateral relating to that letter of credit will be reduced. Accordingly, as the Notes are converted, the Company will be able to access the funds raised from the sale of the Notes in amounts corresponding to the portion of the Notes that are converted or repaid. The $15,000,000 in cash proceeds plus accrued but unpaid interest has been classified as restricted cash on the accompanying consolidated balance sheet as of June 30, 2002 and December 31, 2001. In accordance with APB No. 14, "Accounting for Convertible Debt and Debt Issued with Stock Purchase 13 Warrants" ("APB No. 14"), the Company determined the relative fair value of the Notes to be $9,857,006. The resulting original issuance discount ("OID") of $5,142,994 is being amortized as interest expense, using the effective interest method, over the maturity period of three years. During the six months ended June 30, 2002, the Company recognized a non-cash charge to interest expense of $1,270,675 for the amortization of the OID. In accordance with Emerging Issues Task Force ("EITF") No. 00-27, "Application of Issue No. 98-5 to Certain Convertible Instruments" ("EITF No. 00-27") and EITF No. 98-5, "Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios" ("EITF No. 98-5") and after considering the allocation of the proceeds to the Notes, the Company determined that the Notes contained a beneficial conversion feature ("BCF"). The BCF existed at the commitment date due to the fact that the carrying value of the Notes, after the initial allocation of the proceeds, was less than the fair market value of the Common Stock that was issuable upon conversion. Accordingly, the Company recorded $3,258,468 of BCF as a debt discount on the commitment date. The BCF debt discount is being amortized as interest expense, using the effective interest method, over the maturity period of three years. During the six months ended June 30, 2002, the Company recognized a non-cash charge to interest expense of $825,767 for the amortization of the BCF. A reconciliation of the face amount of the Notes and the carrying value at June 30, 2002 is as follows: Notes carrying value at December 31, 2001 $ 8,288,239 2002 Amortization of: OID, treated as interest expense 1,270,675 BCF, treated as interest expense 825,767 ----------- Notes carrying value at June 30, 2002 $10,384,681 ===========
The OID and BCF will be fully amortized by 2004, at which time the carrying value of the Notes will equal the face value of $15,000,000. ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS All statements in this document that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, subject to risks and uncertainties that could cause actual results to differ materially for Universal Display Corporation from those projected, including, but not limited to, statements regarding Universal Display Corporation's beliefs, expectations, hopes or intentions regarding the future. Forward-looking statements in this document also include statements regarding any financial forecasts or market growth predictions. Universal Display Corporation expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Universal Display Corporation's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. It is important to note that actual outcomes and Universal Display Corporation's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as: uncertainties relating to developments and advances in display technologies, including OLED, TOLED, FOLED, SOLED and PHOLED technology; the expansion of applications for OLED technology; the success of Universal Display Corporation and its development partners in accomplishing technological advances; the ability of Universal Display Corporation to enter into alliances with product manufacturers; product development, manufacturing, and marketing acceptance; uncertainties related to cost and pricing of Universal Display Corporation products; dependence on collaborative partners; and other competition, risks relating to intellectual property of others and the uncertainties of patent protection. 14 GENERAL Since inception, the Company has been exclusively engaged, and for the foreseeable future expects to continue to be exclusively engaged, in funding and performing research and development activities related to the OLED technology and attempting to commercialize such technology. To date, the Company has not generated any significant revenues and does not expect to generate any meaningful revenues for the foreseeable future and until such time, if ever, as it successfully demonstrates that the OLED technology is commercially viable for one or more flat panel display applications and enters into license agreements with third parties with respect to the OLED technology. The Company has incurred significant losses since its inception, resulting in an accumulated deficit of $57,978,421 at June 30, 2002. The rate of loss is expected to increase as the Company's activities increase and losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to achieve sufficient levels of revenue from the commercial exploitation of the OLED technology to support its operations. RESULTS OF OPERATIONS Three Months Ended June 30, 2002 Compared to Three Months Ended June 30, 2001 The Company had a net loss of $5,577,787 (or $0.31 per share) for the quarter ended June 30, 2002 compared to a loss of $4,768,582 (or $0.28 per share) for the same period in 2001. The increase in the net loss was primarily attributed to non-cash interest expense on convertible promissory notes issued in August 2001 (Note 6). The Company earned $364,976 from contract research revenue in the quarter ended June 30, 2002 compared to $254,671 for the same period in 2001. In the quarter ended June 30, 2002, contract research revenue consisted of: (i) $216,738 recognized under a 24-month, $2,977,471 Phase I contract received from the Defense Advanced Research Project Agency (DARPA), (ii) $40,343 recognized under a subcontract received from Princeton University, pursuant to an 18-month, $700,000 contract Princeton received from DARPA, (iii) $43,697 recognized under a two-year DoD Phase II SBIR Army Contract, and (iv) $64,198 under an 11-month, $69,951 Phase I contract received from the US Department of Army. In the same period in 2001, contract research revenue consisted of : (i) $205,309 recognized under an 18-month, $1,500,000 Phase I contract received from the Defense Advanced Research Project Agency (DARPA), (ii) $21,542 recognized under a 2-year, $400,000 Phase II contract from the National Science Foundation (NSF) under the Small Business Technology Transfer Program, and (iii) $27,820 recognized under a 2-year Department of Defense Phase II SBIR contract. The Company also earned $90,050 from the sale of evaluation chemicals to potential OLED display manufacturers during the quarter ended June 30, 2002. The chemicals are used to evaluate the Company's proprietary OLED material system. In the same period in 2001, the Company earned $2,488 in chemical sales. Research and development costs were $3,762,970 for the quarter ended June 30, 2002 compared to $4,063,480 for the same period in 2001. For the quarter ended June 30, 2002, research and development expenses consisted of: (i) costs incurred of $1,620,625 for the development and operations in the Company's facility, (ii) costs incurred of $218,974 for patent applications, prosecutions and other intellectual property rights, (iii) costs incurred of $189,777 to the Company's Research Partners (Note 3) under the 1997 Sponsored Research Agreement and 1997 Amended License Agreement, (iv) non-cash charges of $1,309,826 incurred in connection with the PPG development agreement, and (v) non-cash charges of $423,768 for the amortization of the Company's acquired technology (Note 2 and Note 4). Research and development costs in the same period in 2001 consisted of: (i) costs incurred of $1,349,102 for the development and operations in the Company's facility, (ii) payments of $214,589 to the Company's research partners (see Note 3 in Notes to consolidated financial statements) under the 1997 Sponsored Research Agreement, (iii) costs incurred of $199,960 for patent applications, prosecutions and other intellectual property rights, (iv) non-cash charges of $929,343 incurred in connection with the development agreement with a third party, (v) non-cash charges of $946,718 recorded for warrants and options 15 previously issued to the Scientific Advisory Board members, and (vi) non-cash charges of $423,768 for the amortization of the Company's acquired technology (see Note 2 and Note 4 in Notes to consolidated financial statements). Six Months Ended June 30, 2002 Compared to Six Months Ended June 30, 2001 The Company had a net loss of $10,876,596 (or $0.60 per share) for the six months ended June 30, 2002, compared to $8,547,561 (or $0.51 per share), for the same period in 2001. The increase in the net loss was primarily attributed to non-cash interest expense on convertible promissory notes issued in August 2001 (Note 6). The Company earned $812,059 from contract research revenue for the six months ended June 30, 2002 compared to $454,913 for the same period in 2001. In the six months ended June 30, 2001, contract research revenue consisted of: (i) $500,226 recognized under a 24-month, $2,977,471 Phase I contract received from the Defense Advanced Research Project Agency (DARPA), (ii) $132,000 recognized under a subcontract received from Princeton University, pursuant to an 18-month, $700,000 contract Princeton received from DARPA, (iii) $109,882 recognized under a two-year DoD Phase II SBIR Army Contract, and (iv) $69,951 under an 11-month, $69,951 Phase I contract received from the US Department of Army. In the same period in 2001, contract research revenue was derived from the following: (i) $338,486 recognized under an 18-month, $2,977,471 Phase I contract received from the Defense Advanced Research Project Agency (DARPA), (ii) $67,078 recognized under a two-year, $400,000 Phase II contract from the National Science Foundation (NSF) under the Small Business Technology Transfer Program, (iii) $7,878 recognized under a Department of Defense Phase I, Small Business Innovative Research (SBIR) contract which is completed at this time, (iv) $44,426 recognized under a two-year Department of Defense Phase II SBIR contract, offset by (v) a $2,955 charge against revenue for an overpayment on the final costs of a subcontract under a three-year, $3 million contract Princeton University received from DARPA. The Company also earned $177,893 from the sale of evaluation chemicals to potential OLED display manufacturers during the six months ended June 30, 2002. The chemicals are used to evaluate the Company's proprietary OLED material system. In the same period in 2001, the Company earned $8,298 in chemical sales. The Company has entered into certain joint development and technology evaluation agreements, for which it has received non-refundable advanced license fees. These fees are classified as current liabilities and the Company will record revenue as it is earned. Research and development costs were $7,616,797 for the six months ended June 30, 2002 compared to $7,325,709 for the same period in 2001. For the six months ended June 30, 2002, research and development expenses consisted of: (i) costs incurred of $3,027,686 for the development and operations in the Company's facility, (ii) costs incurred of $534,244 for patent applications, prosecutions and other intellectual property rights, (iii) costs incurred of $354,554 to the Company's research partners (Note 3) under the 1997 Sponsored Research Agreement and the 1997 Amended License Agreement, (iv) non-cash charges of $2,852,777 incurred in connection with the development agreement with a third party, and (v) non-cash charges of $847,536 for the amortization of the Company's acquired technology (Note 2 and Note 4). Research and development costs in the same period in 2001 consisted of: (i) costs incurred of $2,455,197 for the development and operations in the Company's facility, (ii) payments of $429,178 to the Company's research partners (see Note 3 in Notes to consolidated financial statements) under the 1997 Sponsored Research Agreement, (iii) costs incurred of $427,252 for patent applications, prosecutions and other intellectual property rights, (iv) non-cash charges of $1,712,736 recorded for warrants and options previously issued to the Scientific Advisory Board members, (v) non-cash charges of $1,453,810 incurred in connection with the development agreement with a third party, and (vi) non-cash charges of $847,536 for the amortization of the Company's acquired technology (see Note 2 and Note 4 in Notes to consolidated financial statements). 16 LIQUIDITY AND CAPITAL RESOURCES As of June 30, 2002, the Company had cash and cash equivalents of $4,403,484, short-term investments of $2,978,555 and restricted cash of $15,119,781, compared to cash and cash equivalents of $7,883,132, short-term investments of $4,516,199 and restricted cash of $15,162,414 at December 31, 2001. During the six months ended June 30, 2002, the Company received non-refundable cash payments of $716,667 in connection with joint development and technology evaluation agreements, which the Company recorded as deferred license fees. In August 2002, the Company completed a registered direct offering to institutional investors ("the Offering") for 1,277,014 shares of its Common Stock at a price of $5.09 per share. The completion of the Offering resulted in proceeds of approximately $6,038,323, net of estimated costs associated with the completion of the public offering, in the amount of $461,678. In the fourth quarter of 2001, the Company commenced construction on the expansion of its current location in Ewing, New Jersey. The expansion was completed in the first quarter of 2002. As of June 30, 2002, the Company had incurred costs of $1,909,849 relating to the construction and the purchase of equipment for the expansion. The Company anticipates, based on management's internal forecasts and assumptions relating to its operations (including assumptions regarding working capital requirements of the Company, the progress of research and development, the availability and amount of other sources of funding available to Princeton University for research relating to the OLED technology and the timing and costs associated with the preparation, filing and prosecution of patent applications and the enforcement of intellectual property rights), that it has sufficient cash, cash equivalents and short term investments to meet its obligations through at least the current fiscal year. Management believes that additional financing sources for the Company include long-term and short-term borrowings, public and private transactions and receipt of cash upon the exercise of warrants. The 1997 Sponsored Research Agreement requires the Company to pay up to $4.4 million to Princeton University from July 1998 through July 2002. In April 2002, the Company amended the 1997 Sponsored Research Agreement with Princeton providing, iner-alia, for an additional five-year term. The Company is obligated to pay Princeton up to $7.5 million commencing on July 31, 2002 through July 31, 2007. From inception of the Sponsored Research Agreement with Princeton University in 1994, through June 30, 2002, $4,481,822 of this commitment has been funded. Pursuant to its development and license agreement with PPG, the Company is to issue shares of Common Stock, on an annual basis, in consideration of the services provided by PPG. In certain circumstances, the Company may also be required to pay cash to PPG for such services. Substantial additional funds will be required in the future for the research, development and commercialization of OLED technology, obtaining and maintaining intellectual property rights, working capital and other purposes, the timing and amount of which is difficult to ascertain. There can be no assurance that additional funds will be available when needed, or if available, on commercially reasonable terms. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK The Company does not utilize financial instruments for trading purposes and holds no derivative financial instruments, which could expose the Company to significant market risk. The Company's primary market risk exposure with regard to financial instruments is to changes in interest rates, which would impact interest income earned on investments. PART II. OTHER INFORMATION ITEM 1. NONE ITEM 2. Changes in Securities/Use of Proceeds (a) None 17 (b) None (c) None. (d) None ITEM 3. NONE ITEM 4. Submission of Matters to a Vote of Security Holders (a) The Company held its 2002 Annual Meeting of Shareholders on June 27, 2002. (b) Per Instruction 3 to Item 4 of Form 10-Q, no response is required. (c) The matters voted upon at the annual meeting, and the results of the vote on each such matter, are set forth below: 1. Election of seven directors. The result of the vote tabulated at the meeting for the following seven director nominees is set forth as follows, opposite their respective names:
Name Number of Votes For Number of Votes Against --------------------- ------------------- ----------------------- Steven V. Abramson 17,005,181 198,424 Lawrence Lacerte 17,015,481 188,124 Elizabeth H. Gemmill 16,829,077 374,528 Leonard Becker 16,829,077 374,528 C. Keith Hartley 16,829,077 374,528 Sidney D. Rosenblatt 17,005,181 198,424 Sherwin I. Seligsohn 17,005,181 198,424
2. Proposal to increase the number of shares of the Company's Common Stock subject to the Company's Stock Option Plan to 3,800,000 from 2,800,000. The result of the vote tabulated at the meeting for the ratification and approval of the aforementioned proposal was as follows: Number of Votes FOR 8,059,802 Number of Votes AGAINST 1,268,362 Number of Abstentions 71,181
ITEM 5. NONE ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K (A) EXHIBITS: 99.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 99.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (B) REPORTS ON FORM 8-K: None. 18 SIGNATURES In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. UNIVERSAL DISPLAY CORPORATION /s/ Sidney D. Rosenblatt Date: August 14, 2002 ------------------------------- Sidney D. Rosenblatt (Executive Vice President, Chief Financial Officer, Treasurer and Secretary) 19